International Forum on research and development of major innovative drugs and disease models held in Chengdu

The forum focused on innovative drugs and disease models in major fields such as metabolic system diseases, immune system diseases and central nervous system diseases More than 150 well-known experts and professors from clinical medicine, drug research and development and drug review fields in Europe, America and Mainland China attended the forum The international forum is supported by the Sichuan provincial science and technology department and the Chengdu high tech Zone Management Committee It is jointly sponsored by Sichuan Beauty Science and Technology Group Co., Ltd., Tianfu life science and Technology Park, CISCO Pharmaceutical Group Limited by Share Ltd, Chengdu University, Chengdu Tianhe biological medicine science and Technology Park Co., Ltd Samuel C Dudley, Professor of Brown University, director of Cardiology Department of Rhode Island Hospital & Miriam Hospital, and Zhu Yizhun, Dean of School of pharmacy, Fudan University, China, served as the president of the conference Chengdu high tech Zone is an important industrialization carrier of the national modern science and technology industrial base of traditional Chinese medicine, Chengdu National Bio industrial base, Chengdu National Pharmaceutical export base, Chengdu National hi tech industrialization base of biomedical materials and medical devices By the end of 2013, Chengdu hi tech Zone has gathered 595 biological enterprises In the first three quarters of this year, the biological industry of Chengdu high tech Zone achieved rapid development, with an increase of 23.7% in industrial added value On September 20 of this year, Chengdu hi tech Zone officially released several policies to support strategic emerging industry enterprises to accelerate their development The biological industry is one of its main strategic directions At present, Chengdu hi tech Zone has become the first choice for famous biomedical enterprises at home and abroad to settle in Western China It has become a common topic for participants to pay attention to the trend and thinking of disease model promoting new drug research and development, and how to promote the innovative development of biomedical industry At the one-day forum, from West China Hospital of Sichuan University, the Third Military Medical University, Fudan University Medical School, Covance company of the United States, University of Florida Medical School of the United States, Merck Research Laboratory of the United States 14 experts and scholars from international medical institutions, laboratories and research institutes, such as laboratories, Washington University School of medicine, the Department of science and technology of National Academy of medicine, etc., delivered keynote speeches on the development of new drugs based on major human disease models of non-human primates and related fields "Cooperation with top scientific research institutes, professional parks and laboratories in biomedical field at home and abroad has become the only way for enterprises to develop new drugs." Zeng Wen, President of Sichuan animal science and Technology Group Co., Ltd., said the international forum aims to strengthen the deep cooperation between the various R & D teams in the field of subdivision, and further improve the construction of the new bio pharmaceutical screening technology platform based on the Sichuan's biomedical industry, which is based on the human non-human primates According to the introduction, the technology platform has established a major primate human disease model, disease animal background database, and in the future, it can form a very precious and valuable animal disease model resource for innovative drug research and development in the world Zeng Wen said that the experts at the meeting highly recognized the important value of the technology platform, and fully recognized the development environment and policy of biomedical industry in Sichuan and Chengdu "Through this forum, we have reached cooperation intention with many parties around the world, which will play a catalytic role in promoting new drug research and development in relevant fields in Sichuan and even in the world." "Biopharmaceutical R & D is a long-lasting battle, and it is very important to establish an innovation system and carrier to support the R & D process." Chengdu high tech Zone, said the relevant person in charge At present, Chengdu high tech Zone has initially formed a new drug R & D system including drug discovery, drug development, pre clinical evaluation, clinical trials, pilot production and other whole process There are 21 biomedical public technology platforms including pre clinical research (GLP) public technology platform, biomedical analysis and testing public technology platform, natural drug engineering technology research public technology platform, and leading drug development platform There are 237 research projects (drugs and medical devices) in the area, including six new class I drugs that have entered the clinical stage, including DATR for injection of digoxin, chlorogenic acid for injection, a new class I new drug of biological anticancer chemistry in Chapter IX In terms of carrier construction, at present, Chengdu high tech Zone has built two biological professional parks, namely Tianfu life science and Technology Park and Tianhe biological medicine incubator By the end of 2013, Chengdu high tech Zone has gathered 595 biological enterprises, with 25000 industrial employees, including more than 2000 with master's degree and above, and 9 with national "thousand talents plan"; the industrial area is about 2 square kilometers, and it has been awarded the national base of traditional Chinese medicine modernization science and technology, Chengdu National biological industry base, Chengdu national medicine export base, Chengdu National biological medicine High tech industrialization base of materials and medical devices According to reports, in the first three quarters of this year, the biological industry of Chengdu high tech Zone developed rapidly, with an increase of 23.7% in industrial added value As of September this year, the biological industry of Chengdu high tech Zone has 38 Industrial Enterprises above the designated size, with an output value of 7.05 billion yuan, a year-on-year increase of 24%; and the added value of 2.97 billion yuan, a year-on-year increase of 26% On September 20 of this year, Chengdu hi tech Zone issued several policies to support strategic emerging industry enterprises to accelerate development The biological industry is one of its main strategic directions At present, Chengdu hi tech Zone has become the first choice for famous biomedical enterprises at home and abroad to settle in Western China.